These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25358603)

  • 81. Clinical trials with rasagiline: evidence for short-term and long-term effects.
    Siderowf A; Stern M
    Neurology; 2006 May; 66(10 Suppl 4):S80-8. PubMed ID: 16717255
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
    Olanow CW; Rascol O; Hauser R; Feigin PD; Jankovic J; Lang A; Langston W; Melamed E; Poewe W; Stocchi F; Tolosa E;
    N Engl J Med; 2009 Sep; 361(13):1268-78. PubMed ID: 19776408
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Entacapone. A review of its use in Parkinson's disease.
    Holm KJ; Spencer CM
    Drugs; 1999 Jul; 58(1):159-77. PubMed ID: 10439935
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect
    Nagai M; Hattori N
    Nihon Yakurigaku Zasshi; 2020; 155(3):187-194. PubMed ID: 32378642
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis.
    Li J; Lou Z; Liu X; Sun Y; Chen J
    Eur Neurol; 2017; 78(3-4):143-153. PubMed ID: 28813703
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Rasagiline induced hypersexuality in Parkinson's disease.
    Reyes D; Kurako K; Galvez-Jimenez N
    J Clin Neurosci; 2014 Mar; 21(3):507-8. PubMed ID: 24055209
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.
    Hauser RA; Stocchi F; Rascol O; Huyck SB; Capece R; Ho TW; Sklar P; Lines C; Michelson D; Hewitt D
    JAMA Neurol; 2015 Dec; 72(12):1491-500. PubMed ID: 26523919
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
    Shen T; Ye R; Zhang B
    Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Adjunct rasagiline to treat Parkinson's disease with motor fluctuations: a randomized, double-blind study in China.
    Zhang Z; Shao M; Chen S; Liu C; Peng R; Li Y; Wang J; Zhu S; Qu Q; Zhang X; Chen H; Sun X; Wang Y; Sun S; Zhang B; Li J; Pan X; Zhao G
    Transl Neurodegener; 2018; 7():14. PubMed ID: 29988514
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Rasagiline in the pharmacotherapy of Parkinson's disease--a review.
    Rascol O
    Expert Opin Pharmacother; 2005 Oct; 6(12):2061-75. PubMed ID: 16197359
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson's Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study.
    Su W; Liang Z; Mao W; Shao M; Hu X; Wu Y; Wei W; Liu Z; Zhang K; Tang B; Cao S; Song Z; Chen H
    Drug Saf; 2023 Jul; 46(7):637-646. PubMed ID: 37195560
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease.
    Attia ; Ahmed H; Gadelkarim M; Morsi M; Awad K; Elnenny M; Ghanem E; El-Jaafary S; Negida A
    CNS Neurol Disord Drug Targets; 2017; 16(2):169-175. PubMed ID: 27823574
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Safety and effectiveness of rasagiline in patients with Parkinson's disease in Japan: a post-marketing surveillance study.
    Hattori N; Kajita M; Fujimoto S; Izutsu M; Fernandez J
    Expert Opin Drug Saf; 2024 Jan; 23(1):79-88. PubMed ID: 38124528
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
    Avila A; Caballol N; Martín-Baranera M; Gómez-Ruiz I; Balagué-Marmaña M; Planas-Ballvé A; Cardona X
    Acta Neurol Scand; 2019 Jul; 140(1):23-31. PubMed ID: 30963543
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Effects of rasagiline on Parkinson's Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson's disease: A post-hoc analysis of clinical trials in Japan.
    Hattori N; Takeda A; Hanya Y; Kitagawa T; Arai M; Furusawa Y; Mochizuki H; Nagai M; Takahashi R
    PLoS One; 2022; 17(1):e0262796. PubMed ID: 35077474
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
    Parkinson Study Group
    Arch Neurol; 2002 Dec; 59(12):1937-43. PubMed ID: 12470183
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis.
    Negida A; Ghaith HS; Fala SY; Ahmed H; Bahbah EI; Ebada MA; Aziz MAE
    Neurol Sci; 2021 Aug; 42(8):3135-3143. PubMed ID: 34014397
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
    Ahlskog JE; Uitti RJ
    Neurology; 2010 Apr; 74(14):1143-8. PubMed ID: 20368634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.